Treatment of pulmonary hypertension (PH) in neonates is a major challenge on the
intensive care unit and involves high morbidity and mortality. However we have
gained considerable insights into the pathophysiology of PH leading to an increasing
number of possible treatment targets. Translation of these novel targets into clinical
application requires multi-centre randomized controlled trials. Furthermore,
considering the underlying pathology is important in therapy choice. New therapies
will not only target vasodilatation, but also reduce vascular remodeling and enhance
postnatal lung development. This review provides an overview of currently available
drugs and promising new targets in the treatment of PH in newborns.
No comments:
Post a Comment